🇺🇸 FDA
Patent

US 12263180

Method for treatment of COVID-19-associated conditions

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 12263180 (Method for treatment of COVID-19-associated conditions) held by Rigel Pharmaceuticals, Inc. expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
39
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K31/155, A61K31/245